At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ITRM Iterum Therapeutics Plc
Trading 12-11 15:49:41 EST
0.4731
+0.0131
+2.85%
High0.4898Low0.4523Vol301.44K
Open0.4523D1 Closing0.4600Amplitude8.15%
Mkt Cap24.97MTradable Cap24.78MTotal Shares52.79M
T/O142.37KT/O Rate0.58%Tradable Shares52.38M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Iterum Therapeutics Provides Business Update
Reuters  ·  12-05
BRIEF-Iterum Therapeutics Provides Business Update
Iterum Therapeutics Plc - Rebate Agreement Signed With Top Medicare Part D Manager
THOMSON REUTERS  ·  12-05
Iterum Therapeutics Plc - Rebate Agreement Signed With Top Medicare Part D Manager
Director Michael W. Dunne Acquires Common Shares of Iterum Therapeutics plc
Reuters  ·  11-20
Director Michael W. Dunne Acquires Common Shares of Iterum Therapeutics plc
Iterum Therapeutics Q3 Adjusted EPS USD -0.16
THOMSON REUTERS  ·  11-14
Iterum Therapeutics Q3 Adjusted EPS USD -0.16
Iterum Therapeutics Plc: Extends Cash Runway Into Q2 2026
THOMSON REUTERS  ·  11-14
Iterum Therapeutics Plc: Extends Cash Runway Into Q2 2026
Press Release: Iterum Therapeutics Reports Third Quarter 2025 Financial Results
Dow Jones  ·  11-14
Press Release: Iterum Therapeutics Reports Third Quarter 2025 Financial Results
Top Stocks With Earnings This Week: Plug, Oklo, Circle And More
Benzinga  ·  11-10
Top Stocks With Earnings This Week: Plug, Oklo, Circle And More
Iterum Therapeutics PLC expected to post a loss of 11 cents a share - Earnings Preview
Reuters  ·  11-07
Iterum Therapeutics PLC expected to post a loss of 11 cents a share - Earnings Preview
Maxim Group Sticks to Their Buy Rating for Iterum Therapeutics (ITRM)
TIPRANKS  ·  10-02
Maxim Group Sticks to Their Buy Rating for Iterum Therapeutics (ITRM)
Iterum Therapeutics sees cash runway into 2026
TIPRANKS  ·  09-19
Iterum Therapeutics sees cash runway into 2026
Iterum Therapeutics - Will Continue to Explore All Available Financing Opportunities to Extend Its Operating Runway
THOMSON REUTERS  ·  09-19
Iterum Therapeutics - Will Continue to Explore All Available Financing Opportunities to Extend Its Operating Runway
Iterum Therapeutics plc Conducted Annual General Meeting
Reuters  ·  09-11
Iterum Therapeutics plc Conducted Annual General Meeting
Iterum Therapeutics Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Rule
Reuters  ·  08-29
Iterum Therapeutics Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Rule
Iterum Therapeutics Launches Orlynvah™, the First and Only Oral Penem Antibiotic in the U.S.
THOMSON REUTERS  ·  08-20
Iterum Therapeutics Launches Orlynvah™, the First and Only Oral Penem Antibiotic in the U.S.
Michael W. Dunne, Director, Reports Acquisition of Common Shares of Iterum Therapeutics plc
Reuters  ·  08-12
Michael W. Dunne, Director, Reports Acquisition of Common Shares of Iterum Therapeutics plc
Iterum Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Reuters  ·  08-05
Iterum Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Iterum Therapeutics Reports Adjusted Net Loss per Share; Differences Highlighted in Reconciliation Tables
Reuters  ·  08-05
Iterum Therapeutics Reports Adjusted Net Loss per Share; Differences Highlighted in Reconciliation Tables
Iterum Therapeutics Plc: on Track to Launch Orlynvah This Month for Treatment of Uncomplicated Urinary Tract Infections
THOMSON REUTERS  ·  08-05
Iterum Therapeutics Plc: on Track to Launch Orlynvah This Month for Treatment of Uncomplicated Urinary Tract Infections
Iterum Therapeutics Plc - Agreement Includes Confidentiality and Liability Provisions - SEC Filing
THOMSON REUTERS  ·  08-05
Iterum Therapeutics Plc - Agreement Includes Confidentiality and Liability Provisions - SEC Filing
Iterum Therapeutics PLC expected to post a loss of 11 cents a share - Earnings Preview
Reuters  ·  08-01
Iterum Therapeutics PLC expected to post a loss of 11 cents a share - Earnings Preview

Introduction

Company Name.
Iterum Therapeutics Plc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Issue price:
--